PHARMACY

Rite Aid offering seasonal flu shots

BY David Salazar

CAMP HILL, Pa. — Rite Aid has announced the availability of seasonal flu shots at its pharmacies ahead of flu season. The company said that its immunizing pharmacists would be administering the flu vaccine at its more than 4,500 pharmacy locations.

“Getting a flu shot as soon as the vaccine becomes available is the single best way to protect yourself from the flu and maintain one’s overall health, while also helping prevent the spread of seasonal flu,” Rite Aid EVP pharmacy Jocelyn Konrad said. “With more than 11,000 certified immunizing pharmacists and thousands of locations across the country, getting a flu shot at Rite Aid today will help protect you throughout flu season.”

Rite Aid this year is offering a quadrivalent flu vaccine, offering protection against four strains of the flu — influenza A H3N2, A H1N1 and two strains of influenza B — as well as standard trivalent vaccine and FLUAD, a trivalent vaccine with an adjuvant to create a stronger immune response, approved for patients ages 65 years and older.

Most insurance plans, including Medicare Part B cover flu shots, the company said, adding that they would be available during regular pharmacy hours. The Centers for Disease Control and Prevention recommend the flu vaccine by the end of October for everyone ages six months and older.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

FDA gives OK to Lupin’s Lidex generic

BY David Salazar

SILVER SPRING, Md. — The Food and Drug Administration has approved Lupin’s generic of Lidex (fluocinonide topical solution, 0.05%), the company recently announced.

The drug is indicated to relieve inflammatory and pruritic manifestations of dermatoses that are responsive to corticosteroid treatment. The drug had U.S. sales of $32.4 million for the 12 months ended March 2017, according to QuintilesIMS data.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

PHARMACY

Silvergate Pharmaceuticals announces Xatmep availability

BY David Salazar

DENVER — The first methotrexate oral solution approved by the Food and Drug Administration, Xatmep, is now available, manufacturer Silvergate Pharmaceuticals announced Monday. The drug, approved by the FDA in April, is indicated to treat acute lymphoblastic leukemia and manage polyarticular juvenile idiopathic arthritis in pediatric patients.

"Xatmep is an exciting product in that it provides an FDA-approved, ready-to-use oral solution of methotrexate for children without the need for needles, crushing of tablets, or compounding into a liquid formulation," Silvergate president and CEO Frank Segrave said. "As a company, we continue to focus on pediatric medications that are safe, effective, and readily available."

The oral solution requires no preparation, the company said, noting that it requires refrigeration but can be stored at room temperature for up to 60 days after dispensing to the patient. The drug comes with a boxed warning about the risk of severe toxic reactions, including embryo-fetal toxicity, bone marrow suppression, serious infections, hepatic toxicity and pulmonary toxicity, among others.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES